Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Pfizer Inc. Stock

Price
 
€34.70
0.3
0.870%
Target price
€42.39
06.12.19 / Tradegate WKN: 852009 / Symbol: PFE / Name: Pfizer / Stock / Pharmazeutika
Latest predictions
-
14.11.19
buy
€42.39
20.02.19
buy
€79.83
26.06.18
buy
€36.98
07.04.16
buy
Your prediction

Pfizer Inc. Stock

Pfizer Inc. gained 0.870% compared to yesterday.
Our community is currently high on Pfizer Inc. with 4 Buy predictions and 0 Sell predictions.
As a result the target price of €42.00 shows a positive potential of 21.037% compared to the current price of €34.70 for Pfizer Inc..
Register To Post

Other discussions about Pfizer Inc. Stock

New thread

News

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference


Pfizer Inc. invites investors and the general public to listen to a webcast of a discussion with Mikael Dolsten, Chief Scientific Officer and President, Worldwide Research, Development and Medical

FDA Approves Pfizer’s Biosimilar, ABRILADA™ (adalimumab-afzb) for Multiple Inflammatory Conditions


Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the

Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals: https://mms.businesswire.com/media/20191115005062/en/756796/5/4121854_GUARD-AF_Infographic_11.12.jpg
Bristol-Myers Squibb and Pfizer Announce Randomized, Controlled Trial to Evaluate the Effect of Atrial Fibrillation Screening on Health Outcomes in Older Individuals


The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly

Mylan and Pfizer Announce Viatris as the New Company Name in the Planned Mylan-Upjohn Combination


Mylan N.V. (NASDAQ: MYL) and Pfizer Inc. (NYSE: PFE) today announced that the name of the new company to be formed by the planned combination of Mylan and Upjohn, a division of Pfizer, will be

Pfizer Announces Results of Phase 3 Study for XELJANZ® (tofacitinib) in Juvenile Idiopathic Arthritis Ahead of Presentation at 2019 American College of Rheumatology/Association of Rheumatology Professionals Annual Meeting


Pfizer Inc. (NYSE: PFE) announced today that positive results from a Phase 3 investigational study of tofacitinib in children and adolescents aged two to less than 18 with juvenile idiopathic